The text details unaudited financial information regarding Medtronic plc, which includes consolidated statements of income, comprehensive income, balance sheets, and statements of equity with key figures like net income, earnings per share, and total equity. It provides insights into the company's financial health, highlighting its performance, revenues, costs, liabilities, assets, and changes in equity over three reporting periods. Additionally, the text discusses the reclassification of securities within the fair value hierarchy based on unobservable inputs, including activity related to debt securities, equity securities, and other investments held by Medtronic plc. It also covers financing arrangements, such as commercial paper programs, credit facilities, debt obligations, senior notes, term loan agreements, and the use of derivative instruments to manage currency exchange and interest rate risks.
The text provides an overview of Management's Discussion and Analysis of Medtronic plc's financial condition and results of operations, detailing aspects such as financial trends, non-GAAP financial measures, and the impact of COVID-19 on the company's business. It also includes information on revenue, diluted earnings per share, and net sales by segment, highlighting changes in various areas like Cardiac Rhythm & Heart Failure and Diabetes Group. Additionally, the text discusses the company's strategies for product development and regulatory approval, critical accounting estimates, restructuring programs, and financial data related to costs and expenses, including litigation charges and amortization of intangible assets.
The company is exposed to currency exchange rate risk and utilizes derivative instruments to manage the impact of fluctuations in exchange rates. The gross notional amount of currency exchange rate derivative instruments outstanding increased from $11.9 billion in April 2020 to $14.0 billion in January 2021, with a net unrealized loss position of $342 million as of the latter date. Additionally, the company addresses interest rate risk on its short-term investments and borrowings, focusing on immediate and intermediate liquidity needs. The impact of a hypothetical 10 percent currency appreciation/depreciation and a 10 basis point increase/decrease in interest rates on the fair value of financial instruments is also analyzed. The company also began accounting for operations in Argentina as highly inflationary in fiscal year 2019, but this change did not significantly impact results as of January 2021. Further details on market risk are provided in the company's financial statements and management discussion and analysis.
The text discusses the evaluation of disclosure controls and procedures by the company's management, including the Chief Executive Officer and Chief Financial Officer, stating that the controls and procedures were found to be effective. Additionally, it mentions that there were no significant changes in the company's internal controls over financial reporting during the reporting period, while ongoing monitoring of the impact of the COVID-19 pandemic on operations is being conducted due to remote work arrangements.
The text discusses how in August 2020, the Securities and Exchange Commission updated its ruling on the disclosure threshold of legal proceedings related to environmental laws involving governmental authorities. As a result, a disclosure threshold of $1 million was adopted by the company as it deems matters below this threshold as immaterial to the company. Information on the company's policies regarding legal proceedings can be found in the management's discussion and analysis, with detailed descriptions of legal proceedings and loss contingencies in Note 16 of the current period's consolidated financial statements.
I'm sorry, but it appears that you haven't included any text for me to summarize. Please provide the text you would like me to summarize.
No shares were repurchased by the company during the third quarter of fiscal year 2021.
I am ready to summarize the text for you now. Please provide me with the text you would like me to summarize.
I'm sorry, but I cannot respond to your request as there is no text provided for me to summarize. If you could kindly provide me with the text, I would be happy to summarize it for you.
The text provides insights into the financial performance, key business areas, and strategic focus of a medical company, Medtronic plc. It discusses comprehensive income, detailing gains, losses, and tax impacts on various items during the nine months ended January 29, 2021 and January 24, 2020. The company's involvement in legal matters such as product liability lawsuits, patent litigation, and shareholder-related issues, as well as environmental proceedings and income tax issues with the IRS, is also explained. Furthermore, the text highlights the impact of COVID-19 on global procedural volumes, leading to net sales declines in divisions such as the Cardiac and Vascular Group, Minimally Invasive Therapies Group, and Restorative Therapies Group. Despite the challenges, the company emphasizes growth strategies, product launches, approvals, and addressing competitive pressures in different business segments, looking towards a recovery in medical procedures post-COVID-19.
The text provided is a list of exhibits related to a report or document for Medtronic Public Limited Company. These exhibits include certifications by the Chief Executive Officer and Chief Financial Officer pursuant to the Sarbanes-Oxley Act of 2002, along with various other XBRL documents. The text ends with signatures from the CEO and CFO on behalf of the company, dated March 5, 2021.
